The Insulin Resistance Intervention after Stroke Trial A randomized, placebo-controlled trial of pioglitazone, compared with placebo, for prevention of stroke and myocardial infarction after ischemic stroke and transient ischemic attack

Trial Profile

The Insulin Resistance Intervention after Stroke Trial A randomized, placebo-controlled trial of pioglitazone, compared with placebo, for prevention of stroke and myocardial infarction after ischemic stroke and transient ischemic attack

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Insulin resistance; Myocardial infarction; Stroke
  • Focus Therapeutic Use
  • Acronyms IRIS
  • Most Recent Events

    • 30 Oct 2017 Results of planned secondary analysis assessing efficacy published in the Circulation.
    • 18 Sep 2017 Results published in the JAMA Neurology.
    • 28 Feb 2017 Results of a secondary analysis investigating the effects of pioglitazone on acute coronary syndromes (ACS) (MI and unstable angina) among IRIS participants, published in the Circulation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top